Signifor Injection Dosage
Generic name: PASIREOTIDE 0.3mg in 1mL
Dosage form: injection
Medically reviewed on March 9, 2018.
Recommended Dosage Range
The recommended dosage range of SIGNIFOR is 0.3 to 0.9 mg by subcutaneous injection twice a day. The recommended initial dose is either 0.6 mg or 0.9 mg twice a day. Titrate dose based on response and tolerability.
Patients should be evaluated for a treatment response [clinically meaningful reduction in 24-hour urinary free cortisol (UFC) levels and/or improvement in signs or symptoms of the disease] and should continue receiving therapy with SIGNIFOR as long as benefit is derived [see Clinical Studies (14)]. Maximum urinary free cortisol reduction is typically seen by two months of treatment [see Clinical Studies (14)]. For patients who are started on 0.6 mg twice a day, a dosage increase to 0.9 mg twice a day may be considered based on the response to the treatment, as long as the 0.6 mg dosage is well tolerated by the patient.
Management of suspected adverse reactions may require temporary dose reduction of SIGNIFOR. Dose reduction by 0.3 mg decrements per injection is suggested.
Recommendations Prior to Initiation of SIGNIFOR
Prior to the start of SIGNIFOR, patients should have baseline levels of the following:
- fasting plasma glucose [see Warnings and Precautions (5.2)]
- hemoglobin A1c [see Warnings and Precautions (5.2)]
- liver tests [see Warnings and Precautions (5.4)]
- serum potassium and magnesium levels [see Warnings and Precautions (5.3)]
Patients should also have a baseline electrocardiogram and gallbladder ultrasound [see Warnings and Precautions (5.3, 5.5)].
Treatment of patients with poorly controlled diabetes mellitus should be intensively optimized with anti-diabetic therapy prior to starting SIGNIFOR [see Warnings and Precautions (5.2)].
Dosage in Patients with Hepatic Impairment
For patients with moderate hepatic impairment (Child-Pugh B), the recommended initial dosage is 0.3 mg twice a day and the maximum dosage is 0.6 mg twice a day. Avoid the use of SIGNIFOR in patients with severe hepatic impairment (Child-Pugh C) [see Use in Specific Populations (8.6)].
Important Administration Instructions
Instruct patients to:
- Refer to the FDA-approved patient labeling (Instructions for Use) for detailed administration instructions.
- Prior to injection, visually inspect the product for particulate matter and discoloration. Do not use if particulates and/or discoloration are observed.
- Avoid injection in sites showing signs of inflammation or irritation.
- Prior to injection, gently pinch the skin at the injection site and hold the needle/syringe at an angle of approximately 45 degrees.
- Administer SIGNIFOR subcutaneously by self-injection into the top of the thigh or the abdomen.
- Avoid multiple subcutaneous injections at the same site within short periods of time. Use of the same injection site for two consecutive injections is not recommended.
- If a dose of SIGNIFOR is missed, the next injection should be administered at the scheduled time. Do not double doses to make up for a missed dose.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about Signifor (pasireotide)
- Signifor Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 0 Reviews
- Drug class: somatostatin and somatostatin analogs
- Signifor (Pasireotide Extended-Release Injection)
- Signifor (Pasireotide Injection)
- Signifor (Advanced Reading)
Other brands: Signifor LAR